PARP1 and ovarian carcinoma: However, it is noteworthy that the tumor types varied considerably in these two populations, with nine of the 13 patients of GIS ≥33 in the exploratory biomarker analysis having tumor types known to be sensitive to PARP inhibitor (i.e., ovarian cancer, prostate cancer, or breast cancer).